| More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma T Jelinek, R Bezdekova, D Zihala, T Sevcikova, A Anilkumar Sithara, ... Journal of clinical oncology 41 (7), 1383-1392, 2023 | 31 | 2023 |
| Transcriptome analysis of diffuse large b-cell lymphoma cells inducibly expressing MyD88 L265P mutation identifies upregulated CD44, LGALS3, NFKBIZ, and BATF as downstream … M Turi, A Anilkumar Sithara, L Hofmanová, D Žihala, D Radhakrishnan, ... International Journal of Molecular Sciences 24 (6), 5623, 2023 | 7 | 2023 |
| iCOMIC: a graphical interface-driven bioinformatics pipeline for analyzing cancer omics data A Anilkumar Sithara, DP Maripuri, K Moorthy, SS Amirtha Ganesh, ... NAR Genomics and Bioinformatics 4 (3), lqac053, 2022 | 4 | 2022 |
| Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine M Zátopková, T Ševčíková, V Fanfani, Z Chyra, L Říhová, R Bezděková, ... Blood Advances 6 (2), 368-372, 2022 | 4 | 2022 |
| Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy O Venglar, V Kapustova, A Anilkumar Sithara, D Zihala, L Muronova, ... British Journal of Haematology 204 (4), 1439-1449, 2024 | 3 | 2024 |
| Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma O Venglar, T Sevcikova, AA Sithara, V Kapustova, J Vrana, D Zihala, ... Blood 138, 2764, 2021 | 3 | 2021 |
| Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors T Jelinek, D Zihala, T Sevcikova, A Anilkumar Sithara, V Kapustova, ... Leukemia, 1-11, 2024 | 2 | 2024 |
| Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics D Ogiya, Z Chyra, SJ Verselis, M O’Keefe, J Cobb, I Abiatari, S Talluri, ... Blood Cancer Journal 13 (1), 23, 2023 | 1 | 2023 |
| Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets T Jelinek, D Zihala, T Sevcikova, V Kapustova, H Sahinbegovic, ... Blood 138, 2680, 2021 | 1 | 2021 |
| P-344 Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment T Jelinek, D Zihala, T Sevcikova, AA Sithara, V Kapustova, ... Clinical Lymphoma Myeloma and Leukemia 23, S228-S229, 2023 | | 2023 |
| P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS D Zihala, T Jelinek, T Sevcikova, AA Sithara, V Kapustova, D Bilek, ... HemaSphere 7 (S3), e003730a, 2023 | | 2023 |
| PB2397: TRANSCRIPTOME ANALYSIS OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS EXPRESSING MYD88 L265P REVEALS CD44, LGALS3, NFKBIZ AND BATF AS DOWNSTREAM TARGETS OF ONCOGENIC NF-ΚB … M Turi, AA Sithara, L Hofmanová, D Žihala, D Radhakrishnan, A Vdovin, ... HemaSphere 7 (S3), e4265786, 2023 | | 2023 |
